IGS1 Stock Chart & Stats
€0.23
€0.00(0.00%)
At close: 4:00 PM EDT
€0.23
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.21 - €0.39
Previous CloseN/A
Volume0.00
Average Volume (3M)1.02K
Market Cap
€21.61M
Enterprise Value€26.51
Total Cash (Recent Filing)€235.00K
Total Debt (Recent Filing)€933.00K
Price to Earnings (P/E)―
Beta0.70
Next Earnings
Aug 12, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding100,091,320
10 Day Avg. Volume936
30 Day Avg. Volume1,023
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)4.08
Price to Sales (P/S)21.08
P/FCF Ratio-4.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€4.77Price Target Upside1974.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.08
Revenue Forecast (FY)€947.21K
Bulls Say, Bears Say
Bulls Say
Low Leverage / Debt-Free Balance SheetHaving essentially no debt is a durable structural strength for a clinical-stage biotech. It reduces fixed cash obligations, preserves flexibility to fund R&D or absorb trial delays, and lowers bankruptcy risk, improving the firm's ability to pursue regulatory milestones without immediate interest burdens.
Improved Cash Generation TrendsFree cash flow tracking close to net income and improvement versus prior peaks indicates cash burn has moderated. For a R&D-focused company this suggests improving cash efficiency and that much of losses are non-cash, which lengthens runway and reduces near-term financing intensity compared with prior periods.
Extended Bank Facility Preserves Credit AccessMaintaining a $12M banking facility with mostly unchanged terms provides durable optionality to fund operations or bridge development milestones. Contractual access to credit reduces reliance on volatile equity markets and supports execution of multi-month clinical programs and regulatory activities.
Bears Say
Sharp Revenue Decline And Margin CompressionA sudden, severe revenue contraction and large gross margin compression signal weakened commercial traction or one-time revenue loss, undermining scalable revenue streams. Over months this reduces operating leverage and makes it harder to finance continued R&D internally or negotiate favorable partner deals.
Persistent Heavy Losses And Deep Negative MarginsExtremely negative operating and net margins reflect structural unprofitability relative to revenues. Sustained large losses increase the probability of future dilution, limit reinvestment capacity, and hinder ability to demonstrate unit economics to partners or payors, pressuring long-term sustainability without new capital.
Eroding Equity CushionMaterial decline in shareholders' equity over several years reduces the balance sheet buffer against adverse outcomes. A thinner equity base weakens negotiating leverage with lenders and partners, raises insolvency risk in adverse scenarios, and makes non-dilutive financing or strategic M&A less attainable.
IGC Pharma News
IGS1 FAQ
What was IGC Pharma’s price range in the past 12 months?
IGC Pharma lowest stock price was €0.21 and its highest was €0.39 in the past 12 months.
What is IGC Pharma’s market cap?
IGC Pharma’s market cap is €21.61M.
When is IGC Pharma’s upcoming earnings report date?
IGC Pharma’s upcoming earnings report date is Aug 12, 2026 which is in 6 days.
How were IGC Pharma’s earnings last quarter?
IGC Pharma released its earnings results on Jun 15, 2026. The company reported -€0.017 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is IGC Pharma overvalued?
According to Wall Street analysts IGC Pharma’s price is currently Undervalued.
Does IGC Pharma pay dividends?
IGC Pharma does not currently pay dividends.
What is IGC Pharma’s EPS estimate?
IGC Pharma’s EPS estimate is -0.02.
How many shares outstanding does IGC Pharma have?
IGC Pharma has 100,091,320 shares outstanding.
What happened to IGC Pharma’s price movement after its last earnings report?
IGC Pharma reported an EPS of -€0.017 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.479%.
Which hedge fund is a major shareholder of IGC Pharma?
Currently, no hedge funds are holding shares in DE:IGS1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
IGC Pharma
IGC Pharma, Inc. operates as a pharmaceutical firm, currently in the clinical development phase, dedicated to pioneering novel treatments for Alzheimer's, a debilitating condition. The company's pipeline includes two experimental drug candidates aimed at this disease: IGC-AD1, which is presently undergoing a Phase 2 clinical study for addressing agitation associated with Alzheimer's-related dementia, and TGR-63, which is still in its preclinical stage. Beyond its therapeutic development efforts, IGC Pharma also explores the application of artificial intelligence (AI) to advance Alzheimer's research. Established on April 29, 2005, by Ram Mukunda, the company maintains its principal office in Potomac, Maryland.
IGS1 Stock 12 Month Forecast
Average Price Target
€4.77
▲(1974.07% Upside)